Pharmaceutical Giants Face Identical Patent Expiry Risk, But Their Dividend Safety Differs Sharply
Pfizer and Bristol Myers Squibb both confront over $22 billion in annual revenue from drugs losing U.S. exclusivity by 2028, including the shared medication Eliquis, creating pressure on their dividend programs. While Pfizer offers a higher yield at 6% versus Bristol Myers's 4%, Pfizer's cash payout ratio of 89% leaves limited cushion compared to Bristol Myers's 45%, and Pfizer has frozen its quarterly payment since early 2025. Bristol Myers faces a steeper cliff representing 51% of its 2025 revenue but maintains stronger financial flexibility through consistent dividend raises over 17 consecutive years.
Both pharmaceutical firms derive roughly one-third to one-half of their annual revenue from medications entering generic competition within the next few years. Pfizer's business remains relatively diversified, with newer products offsetting patent losses, though the company has halted dividend growth since early 2025 despite maintaining a higher yield. Bristol Myers confronts a more concentrated risk, as two legacy drugs represent the majority of its revenue exposure, yet management has continued raising shareholder payments annually while maintaining substantially lower debt levels relative to earnings power.
Dividend investors relying on pharmaceutical stocks for income could face material changes in payouts if patent cliffs accelerate faster than anticipated or pipeline drugs underperform. Healthcare consumers may see increased access to lower-cost generic alternatives, potentially reducing out-of-pocket costs but also signaling reduced profitability for drug developers—which could affect their capacity to fund research into new treatments. Institutional investors and pension funds holding these positions may need to reassess portfolio assumptions about stable healthcare sector returns over the coming years.